Abstract
Cisplatin (CP) is used to treat various types of cancer. However, its usage is limited due to nephrotoxicity. This study aims to examine the applicability of methylene blue (MB) against CP-induced kidney injuries. In this study, twenty-eight male rats were divided into four groups. Following administration of a single dose of CP (5mg/kg), animals received intraperitoneal injections (IP) of MB (4mg/kg) for seven days. In the final phase of the experiment, serum was collected from rats, with blood urea nitrogen (BUN) and creatinine (Cr) levels measured. Hematoxylin-Eosin (H&E) and Masson's trichrome staining were performed to examine histological changes. Immuno-histological staining was used to evaluate caspase-3 protein expression. The results showed that the MB (4mg/kg) +CP treated rats underwent a lesser weight loss compared to the CP group (p<0.05 and p<0.001, respectively). The kidney weight decreased significantly in the CP +MB group compared to the CP group (p<0.05 and p<001, respectively). BUN and Cr levels that were increased significantly in the serum of the CP group (p<0.001) compared to the control group showed no significant increase in the MB +CP group compared to the control group (p=0.842 and p=0.989, respectively). There was a significant decrease in kidney tissue injuries in the CP +MB compared to the CP group (p<0.001). The glomerular size was recovered in the CP +MB group compared to the CP (p<0.05). The significant increase in the capsular space of the CP group compared to the control group (p<0.001) was attenuated in the CP +MB. MB restored the histological alterations in the kidneys. Treatment with 4mg/kg of MB reduced the expression levels of Caspase-3. In conclusion, this study provides evidence concerning the anti-apoptotic roles of MB in CP-induced kidney damage. In conclusion, MB has a positive impact on kidney function.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.